The global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.
RGEN
Repligen Corp · NASDAQ
News
1 latestNo direct coverage yet · Showing articles that mention RGEN
Headlines link to the publisher. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $RGEN · 0 threads
Sign in to post on $RGEN
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.